Table 1 |
|||
|
Effect of different immunomodulatory therapies on insulin-free period in patients with newly diagnosed type 1 diabetes mellitus |
|||
| Immunomodulating therapy |
Treatment length |
Number of patients free from/total number of patients |
Period free from insulin (average) |
|
|
|||
| Prednisone2 |
12 months (daily use) |
4/17 |
3 months |
| Prednisone + azathioprine4 |
12 months (daily use) |
10/20 |
1 week |
| Azathioprine3 |
12 months (daily use) |
0/24 |
0 |
| Ciclosporin5 |
24 months (daily use) |
53/122 |
10 months |
| Antibody anti-CD36 |
E.V. application 6 days in a row |
0 |
0 |
| Heat shock protein7 |
1 S.C. application in time 0, + 1 and + 6 months |
0 |
0 |
| Anti-thymocyte globulin8 |
E.V. Applications 4 days in a row |
0 |
0 |
| Glutamic acid decarboxylase9 |
2 subcutaneous applications with 1-month interval |
0 |
0 |
|
|
|||
|
Couri and Voltarelli Diabetology & Metabolic Syndrome 2009 1:19 doi:10.1186/1758-5996-1-19 |
|||
